|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 帕博利珠单抗单用或与放疗联用治疗转移性非小细胞肺癌:两个随机试验的汇总分析显示文摘背景放疗可以提高整个机体对免疫治疗的应答。在Ⅱ期PEMBRO-RT研究和Ⅰ/Ⅱ期MDACC研究中,患有转移性非小细胞肺癌(NSCLC)的患者被随机分配入组,接受免疫治疗(帕博利珠单抗)+放疗联合疗法,或免疫治疗单一疗法。当上述2个研究单独分析时,联合疗法组显示出潜在获益。由于每个研究的样本量较小,缓解率和结局并未显示出统计学意义,然而却有显著的临床获益。因此,本研究进行汇总分析,来判断放疗是否会改善转移性NSCLC患者的免疫治疗应答。方法PEMBRO-RT和MDACC研究纳入标准:患者年龄≥18岁,患有转移性NSCLC,且有≥1处未经放疗照射的病灶,以便进行射野外应答监测。PEMBRO-RT研究纳入曾接受过化疗患者,MDACC研究纳入曾接受过治疗或新诊断患者。2个研究中的患者均未接受过免疫治疗。在PEMBRO-RT研究中患者被等比例随机分配入组,并根据吸烟状态进行分层(分为<10年组和≥10年组)。MDACC研究的患者根据放疗计划可行性被等比例随机分配入2个受试组。由于联合治疗组的干预本质,每个研究中的放疗均不适用盲法。在2个研究中,不论是否进行放疗,均静脉滴入帕博利珠单抗(每3周200 mg)。在PEMBRO-RT研究中,在放疗(24 Gy 3次分割照射)结束后1周给予第1剂帕博利珠单抗。在MDACC研究中,在第1次放疗(50 Gy 4次分割照射或45 Gy 15次分割照射)同时给予帕博利珠单抗。仅检测未经照射病灶的应答。本研究的终点为最佳射野外(远隔)应答率(ARR)、最佳射野外疾病控制率(ACR)、12周时ARR、12周时ACR、无进展生存期(PFS)和总生存期(OS)。2个研究的意向治疗(ITT)人群均纳入分析。PEMBRO-RT研究(NCT02492568)和MDACC研究(NCT02444741)均在ClinicalTrials.gov上注册。发现纳入148例患者,76例接受帕博利珠单抗治疗,72例接受帕博利珠单抗+放疗治疗。所有患者随访时间中位数为33个月[四分位距(IQR):32.4~33.6]。148例患者中124例(84%)组织学特征为非鳞癌,111例(75%)患者曾经接受过化疗。组间没有基线特征差异,包括PD-L1表达状态和转移灶体积。最常见的照射部位为肺转移灶(39%,28/72)、胸腔内淋巴结(21%,15/72)和非原发灶(17%,12/72)。帕博利珠单抗组和联合治疗组的最佳ARR分别为19.7%(15/76)和41.7%(30/72),OR=2.96,95%CI:1.42~6.20,P=0.0039;最佳ACR分别为43.4%(33/76)和65.3%(47/72),OR=2.51,95%CI:1.28~4.91,P=0.0071;PFS中位数分别为4.4(IQR:2.9~5.9)和9.0个月(IQR:6.8~11.2),HR=0.67,95%CI:0.45~0.99,P=0.045;OS中位数分别为8.7(IQR:6.4~11.0)和19.2个月(IQR:14.6~23.8),OR=0.67,95%CI:0.54~0.84,P=0.0004。在汇总分析中没有发现新的安全问题。解读帕博利珠单抗免疫疗法+放疗显著提高转移性NSCLC患者的应答和改善治疗结局。这些结果需要在三期临床试验中进行验证。 | 陈大卫(翻译) 于金明(校对) Willemijn S M E Theelen Vivek Verma Brian P Hobbs Heike M U Peulen Joachim G J V Aerts Idris Bahce Anna Larissa N Niemeijer Joe Y Chang Patricia M de Groot Quynh-Nhu Nguyen Nathan I Comeaux George R Simon Ferdinandos Skoulidis Steven H Lin Kewen He Roshal Patel John Heymach Paul Baas James W Welsh | 2021 | 中华肿瘤防治杂志2021，28，24： | 49 |
| 2 | A Novel RGL2-DOF6 Complex Contributes to Primary Seed Dormancy in Arabidopsis thaliana by Regulating a GATA Transcription Factor显示文摘 | Pratibha Ravindran Vivek Verma Petra Stamm Prakash P. Kumar | 2017 | Molecular Plant2017，10，10： | 12 |
| 3 | Combined treatment of non-small cell lung cancer using radiotherapy and immunotherapy: challenges and updates显示文摘The efficacy of immunotherapy for advanced non-small cell lung cancer(NSCLC)remains unsatisfactory,as the majority of patients either do not experience an objective response or acquire secondary resistance.As a result,several methods to enhance the systemic efficacy of immunotherapy have been investigated,including a large area of active research by combining immunotherapy with radiation therapy(RT).Given the rapidly burgeoning concept of combining immunotherapy and RT for increasing therapeutic benefit,we review the progress in this field thus far and explore further avenues for enhancing this combination.This review commences with a discussion of the only two existing randomized trials(and a pooled analysis)showing that the addition of RT to immunotherapy improves the abscopal response rate,progression-free survival,and overall survival in metastatic NSCLC patients.We then discussed factors and biomarkers that may be associated with a proportionally greater benefit to additional RT,such as low programmed cell death protein ligand 1(PD-L1)status,tumor mutational burden(TMB),and patient’s immune function.Next,the implementation of RT to overcome immunotherapy resistance is discussed,including a mechanistic discussion and methods with which these mechanisms could be exploited.Lastly,the emerging role of low-dose RT is discussed,which may help to overcome inhibitory signals in the tumor stroma that limit T-cell infiltration.Taken together,given the current state of this rapidly expanding realm,these futuristic strategies may be reflected upon to further enhance the efficacy of immunotherapy for a wider group of patients. | Shijie Shang Jie Liu Vivek Verma Meng Wu James Welsh Jinming Yu Dawei Chen | 2021 | Cancer Communications2021，41，11： | 10 |
| 4 | Relationship and interactions of curcumin with radiation therapy显示文摘Curcumin is widely reported to have remarkable medicinal- and antineoplastic- properties. This review details curcumin's relationship with radiotherapy(RT), principally as a radiosensitizer for various malignancies and a radioprotector for normal tissues. First, examples of radiosensitization are provided for various cancers:Pediatric, lymphoma, sarcoma, prostate, gynecologic, pancreas, liver, colorectal, breast, lung, head/neck, and glioma. It is not the purpose of this article to comprehensively review all radiosensitization data; however, high-quality studies are discussed in relationship to currently-controversial RT questions for many cancers, and thus the importance of developing a natural radiosensitizer. Attention is then shifted to radioprotection, for which supporting research is discussed for the following RT toxicities: Dermatitis, pneumonitis, cataractogenesis, neurocognition, myelosuppression, secondary malignancies, and mucositis/enteritis. Though there is fewer data for radioprotection, the overall quality of clinical evidence is higher, and small clinical trials implicating the efficacy of curcumin for RT toxicities(vs placebo/current therapies) are also detailed. Though the overall level of evidence for curcumin as a radiosensitizer and radioprotector is low, it must be recognized that risks of adverse effects are exceedingly low, and clinicians may need to judge the yet-unproven rewards with low toxicity risks. | Vivek Verma | 2016 | World Journal of Clinical Oncology2016，7，3： | 4 |
| 5 | JC virus induces altered patterns of cellular gene expression: Interferon-inducible genes as major transcriptional targets显示文摘 | Saguna Verma Katja Ziegler Praveen Ananthula Juliene K.G. Co Richard J. Frisque Richard Yanagihara Vivek R. Nerurkar | 2005 | Virology2005，，2： | 1 |
| 6 | Enhanced microwave absorption properties in polyaniline and nano-ferrite composite in X-band显示文摘 | S.P. Gairola Vivek Verma Lalit Kumar M. Abdullah Dar S. Annapoorni R.K. Kotnala | 2010 | Synthetic Metals2010，，21： | 1 |
| 7 | Two basic proteins isolated from Clerodendrum inerme Gaertn. are inducers of systemic antiviral resistance in susceptible plants显示文摘 | Vivek Prasad Shalini Srivastava Varsha H.N. Verma | 1995 | Plant Science1995，，1： | 1 |
| 8 | TIPS Can Be Lifesaving in Acute Liver Failure Associated with Portal Vein and Inferior Vena Cava Thrombosis in a Case of Budd Chiari Syndrome Due to Protein S Deficiency显示文摘 | Ashish Verma Gagan Sharma Suyash Mohan Vivek A. Saraswat Sanjay S. Baijal | 2008 | CardioVascular and Interventional Radiology2008，，2： | 1 |
| 9 | 显示文摘 | Gairola S P Verma Vivek Singh A | 2010 | Solid State Com- munications2010，150，： | 1 |
| 10 | Efficient DNA isolation from Emblica officinalis for effective PCR显示文摘 | Vishal Bharmauria Vivek Verma Navjyoti Narang | 2010 | Scientific Research and Essay2010，5，1： | 1 |
| 11 | Gluing Gastric Varices in 2012: Lessons Learnt Over 25 Years显示文摘 | Vivek A Saraswat Abhai Verma | 2012 | Journal of Clinical and Experimental Hepatology2012，，1： | 1 |
| 12 | Pivotal roles of tumor-draining lymph nodes in the abscopal effects from combined immunotherapy and radiotherapy显示文摘Background:Currently,due to synergy enhancement of anti-tumor effects and potent stimulation of abscopal effects,combination therapy with irradiation and programmed cell death protein 1/programmed death-ligand 1(PD-1/PD-L1)immune checkpoint inhibition(immuno-radiotherapy,iRT)has revolutionized the therapeutic guidelines.It has been demonstrated that tumor-draining lymph nodes(TDLN)are essential for effective antitumor immunity induced by radiotherapy,immunotherapy,or iRT.Given that the function of TDLN in iRT remains unclear,this study aimed to investigate the function and mechanism of TDLN in iRT-induced abscopal effects.Methods:The function of TDLN was evaluated using unilateral or bilateral MC38 and B16F10 subcutaneous tumor models with or without indicated TDLN.The flow cytometry,multiple immunofluorescence analysis,and NanoString analysis were utilized to detect the composition and function of the immune cells in the primary and abscopal tumor microenvironment.Additionally,we tempted to interrogate the possible mechanisms via RNA-sequencing of tumor-infiltrating lymphocytes and TDLN.Results:TDLN deficiency impaired the control of tumor growth by monotherapy.Bilateral TDLN removal rather than unilateral TDLN removal substantially curtailed iRT-stimulated anti-tumor and abscopal effects.Furthermore,in the absence of TDLN,the infiltration of CD45+and CD8+T cells was substantially reduced in both primary and abscopal tumors,and the anti-tumor function of CD8+T cells was attenuated as well.Additionally,the polarization of tumor-associated macrophages in primary and abscopal tumors were found to be dependent on intact bilateral TDLN.RNA-sequencing data indicated that impaired infiltration and anti-tumor effects of immune cells partially attributed to the altered secretion of components from the tumor microenvironment.Conclusions:TDLN play a critical role in iRT by promoting the infiltration of CD8+T cells and maintaining the M1/M2 macrophage ratio. | Zhaoyun Liu Zhiyong Yu Dawei Chen Vivek Verma Chenxi Yuan Minglei Wang Fei Wang Qing Fan Xingwu Wang Yang Li Yuequn Ma Meng Wu Jinming Yu | 2022 | Cancer Communications2022，42，10： | 1 |
| 13 | Metabolic Alterations Associated with Host Mediated Systemic Antiviral Resistance显示文摘 | VERMA H N VIVEK P | 1988 | Indian Phytopathology1988，41，3： | 1 |
| 14 | Levels of neutrophil gelatinase-assosciated lipocalin in patients with head and neck squamous cell carcinoma in Indian population from Haryana state显示文摘AIM To study the levels of neutrophil gelatinase associated lipocalin(NGAL) in head and neck squamous cell carcinoma(HNSCC).METHODS This was a non randomized case control study conducted at Department of Biochemistry,in collaboration with Regional Cancer Center over a period of one year.The study population included 50 adult newly diagnosed HNSCC patients reporting in outpatient department at Regional Cancer Center and compared with 50 healthy controls.NGAL was estimated by ELISA technique.Student t test and χ~2 test were applied for comparison of means of study groups.Correlations between groups were analyzed using Pearson correlation coefficient(r) formula.RESULTS Patients with HNSCC exhibited significantly increased levels of NGAL(P < 0.05) as compared to healthy controls(978.88 ± 261.39 ng/mL vs 34.83 ± 7.59 ng/mL).Out of 50,26 patients(52%) were in stage Ⅳ,21(42%) in stage Ⅲ,1(2%) patient in stage Ⅱ and 2(4%) patients were in stage Ⅰ.Metastasis was absent in 98% patients and mean NGAL levels were highest in these patients but P value was not significant.Mean NGAL levels were highest in stage Ⅳ [1041.54 ± 222.15 ng/mL(stage Ⅳ) vs 1040 ± 0.00 ng/mL(stage Ⅰ);900 ± 0.00 ng/mL(stage Ⅱ) and 1031.90 ± 202.55 ng/mL(stage Ⅲ)] and χ~2 test was highly significant(P < 0.001).Thirty-six patients(72%) were having moderately differentiated HNSCC and mean NGAL levels were maximum in patients with well differentiated HNSCC(1164 ± 315.64 ng/mL vs 1013.33 ± 161.19 ng/mL in moderately differentiated and 890 ± 11.55 ng/mL in poorly differentiated) and the results were also highly significant(P < 0.001,χ~2 test).CONCLUSION The present work demonstrates a potential role of NGAL as cancer biomarker and its use in monitoring the HNSCC progression. | Monica Verma Kiran Dahiya Abhishek Soni Rakesh Dhankhar Veena S Ghalaut Aastha Bansal Vivek Kaushal | 2017 | World Journal of Clinical Oncology2017，8，3： | 0 |
| 15 | Target migration from re-inflation of adjacent atelectasis during lung stereotactic body radiotherapy显示文摘Stereotactic body radiotherapy(SBRT) is a widely accepted option for the treatment of medically inoperable early-stage non-small cell lung cancer(NSCLC).Herein,we highlight the importance of interfraction image guidance during SBRT.We describe a case of earlystage NSCLC associated with segmental atelectasis that translocated 15 mm anteroinferiorly due to re-expansion of the adjacent segmental atelectasis following the first fraction.The case exemplifies the importance of crosssectional image-guided radiotherapy that shows the intended target,as opposed to aligning based on rigid anatomy alone,especially in cases associated with potentially 'volatile' anatomic areas. | Bijing Mao Vivek Verma Dandan Zheng Xiaofeng Zhu Nathan R Bennion Abhijeet R Bhirud Maria A Poole Weining Zhen | 2017 | World Journal of Clinical Oncology2017，8，3： | 0 |
| 16 | Utility of starchy,lignocellulosics and cellulosics hydrolysates on cellulase production under liquid state fermentation显示文摘Starch is one of the most abundant renewable carbohydrate reserves of higher plants.It can be used to produce many valuable food products in the food processing industry.Furthermore,starch is also used as an important feedstock in the fermentation industry to produce value-added products.Lignocellulosic materials such as agriculture and forestry wastes are considered as a renewable feedstock for bioenergy production through a biochemical conversion process.Converting lignocellulosic biomass into fuels and chemicals entail a physicochemical pretreatment of the biomass,followed by enzymatic hydrolysis of the polysaccharide components such as cellulose and hemicellulose into monomeric sugars.These sugars can then be further fermented into other desired compounds of interest.During the deconstruction processes,various inhibitory compounds are released due to the partial over-degradation of lignocellulose biomass,which inhibits the cell growth and metabolic capacity of fermenting strains.Cellulosic materials such as waste paper in large quantities can also be used as potentially cheap feedstock for sustainable production of value-added products.The present investigation is mainly focused on the utility of starchy hydrolysates(wheat,potato,and rice)and lignocellulosics hydrolysates(bagasse and wheat straw)in cellulase production under liquid state fermentation.It also depicts the potential of cellulosic hydrolysate(waste newspaper)in product formation. | Nitin Verma Vivek Kumar M.C.Bansal | 2019 | Waste Disposal and Sustainable Energy2019，1，4： | 0 |
| 17 | 非小细胞肺癌放疗联合免疫治疗的研究进展与挑战显示文摘由于部分晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者在免疫治疗后没有产生免疫应答或发生继发性耐药,NSCLC免疫治疗的疗效仍不能令人满意。因此,研究者们开展了多项包括放疗(radiation therapy,RT)联合免疫治疗在内的、致力于增强免疫治疗疗效方法的研究。本研究回顾分析了放疗联合免疫治疗提高NSCLC疗效相关研究的进展,并探索进一步增强这一联合治疗疗效的新途径。首先,我们讨论了目前仅有的两项随机试验(和一项汇总分析)。这些试验表明,免疫治疗联合放疗可提高转移性NSCLC患者的远隔客观缓解率、无进展生存期和总生存期。然后,讨论了与放疗免疫疗效相关的因素和生物标志物,例如低水平的程序性细胞死亡配体1(programmed cell death ligand 1,PD-L1)、肿瘤突变负荷(tumor mutational burden,TMB)和患者免疫功能。接下来,我们讨论了放疗逆转免疫治疗耐药的机制和应对措施。最后,讨论了低剂量放疗有助于调控肿瘤间质中抑制T细胞浸润的抑制信号的新作用。综上所述,通过对上述研究的深入分析使更多NSCLC患者从免疫治疗中获益。 | 尚士洁 刘洁 Vivek Verma 吴萌 James Welsh 于金明 陈大卫 | 2023 | 癌症2023，42，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员